- Home
- RPAY vs SGHT Comparison
RPAY vs SGHT Comparison
Compare RPAY & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | SGHT |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 282.9M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RPAY | SGHT |
|---|---|---|
| Price | $3.05 | $4.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $6.81 | ★ $9.08 |
| AVG Volume (30 Days) | ★ 1.3M | 333.7K |
| Earning Date | 06-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $309,261,000.00 | $77,363,000.00 |
| Revenue This Year | $0.22 | $13.54 |
| Revenue Next Year | $7.12 | $14.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.70 | $2.03 |
| 52 Week High | $5.98 | $9.24 |
Technical Indicators
Market Signals| Indicator | RPAY | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 32.12 |
| Support Level | $2.98 | $3.99 |
| Resistance Level | $3.87 | $4.33 |
| Average True Range (ATR) | 0.20 | 0.37 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 56.78 | 21.74 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.